OBJECTIVE: The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia. METHOD: Subjective experience, psychopathology, and extrapyramidal symptoms were assessed, and D(2) receptor occupancy was determined with [(123)I]iodobenzamide single photon emission computed tomography, in 22 patients whose schizophrenia was stabilized by olanzapine or risperidone. RESULTS: Subjective experience, depression, and negative symptoms were related to dopamine D(2) receptor occupancy, but extrapyramidal symptoms were not. CONCLUSIONS: These results provide preliminary evidence that negative subjective experience is related to high D(2) receptor occupancy. Longitudinal study is required because this relationship may have implications for dosing strategies.
OBJECTIVE: The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia. METHOD: Subjective experience, psychopathology, and extrapyramidal symptoms were assessed, and D(2) receptor occupancy was determined with [(123)I]iodobenzamide single photon emission computed tomography, in 22 patients whose schizophrenia was stabilized by olanzapine or risperidone. RESULTS: Subjective experience, depression, and negative symptoms were related to dopamine D(2) receptor occupancy, but extrapyramidal symptoms were not. CONCLUSIONS: These results provide preliminary evidence that negative subjective experience is related to high D(2) receptor occupancy. Longitudinal study is required because this relationship may have implications for dosing strategies.
Authors: Sarah A Eisenstein; Ryan Bogdan; Ling Chen; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey; Deanna M Barch Journal: J Psychiatr Res Date: 2016-11-17 Impact factor: 4.791
Authors: Gagan Fervaha; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Bruce G Pollock; Shinichiro Nakajima; Philip Gerretsen; Tarek K Rajji; Wanna Mar; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Gary Remington; Ariel Graff-Guerrero Journal: Psychopharmacology (Berl) Date: 2016-08-24 Impact factor: 4.530